ReviewCells2023
Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications.
Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 25 citations in OpenAlex.
- Intrahepatic Platelets Orchestrate Microenvironmental Remodelling and Cellular Crosstalk in Liver Fibrosis.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- New oral anticoagulants and hepatocellular carcinoma among patients with HBV, HCV, and alcoholic liver diseases: a nationwide cohort study.Hepatology international · 2026Article
- Review
- The Effectiveness of Systemic Immune-Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) and Model for End-Stage Liver Disease (MELD) Score in Predicting Prognosis in Portal Vein Thrombosis, a Pilot Study.Diagnostics (Basel, Switzerland) · 2026Article
- Platelet-mediated progression of fatty liver disease in metabolic dysfunction-associated steatohepatitis: a pathophysiological review.Frontiers in medicine · 2026Review
- Liver Innervation in Health and Disease: Neuroimmune-Neurovascular Interface and Future Therapeutic Implications.Biomedicines · 2025Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review.Biomedicines · 2025Review
- Genetic association analysis between LDL-c lowering drugs and portal hypertension using Mendelian randomization analysis.Scientific reports · 2025Article
- Review
- The Impact of Thrombophilia on Maternal and Neonatal Outcomes: A Multisystem Analysis of Clinical, Hematological, and Metabolic Parameters.Journal of clinical medicine · 2025Article
- Identifying a unique signature of sepsis in patients with pre-existing cirrhosis.Critical care (London, England) · 2025Article
- Strain- and sex-dependent variability in hepatic microcirculation and liver function in mice.World journal of gastroenterology · 2025Article
- Microvesicle Tissue Factor Procoagulant Activity Is Elevated and Correlated With Disease Severity in Patients With Cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Relationship between coagulopathy score and survival in critically ill patients with liver cirrhosis and sepsis: a retrospective study.BMC infectious diseases · 2025Article
- The Covert Side of Ascites in Cirrhosis: Cellular and Molecular Aspects.Biomedicines · 2025Review
- Analysis of Factors Related to Pulmonary Nodules in Patients With Fatty Liver: A Large-Scale Cohort Study Based on a Physical Examination Population.International journal of general medicine · 2025Article
- Current perspectives and trends of neutrophil extracellular traps in organ fibrosis: a bibliometric and visualization study.Frontiers in immunology · 2025Review
- Extracellular vesicles: emerging therapeutic agents for liver fibrosis.Extracellular vesicles and circulating nucleic acids · 2025Review
- Article
- Endothelial Dysfunction and Liver Cirrhosis: Unraveling of a Complex Relationship.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrosis is an unavoidable consequence of chronic inflammation. Extracellular matrix deposition by fibroblasts, stimulated by multiple pathways, is the first step in the onset of chronic liver disease, and its propagation promotes liver dysfunction. At the same time, chronic liver disease is characterized by alterations in primary and secondary hemostasis but unlike previously thought, these changes are not associated with an increased risk of bleeding complications. In recent years, the role of coagulation imbalance has been postulated as one of the main mechanisms promoting hepatic fibrogenesis. In this review, we aim to investigate the function of microvascular thrombosis in the progression of liver disease and highlight the molecular and cellular networks linking hemostasis to fibrosis in this context. We analyze the predictive and prognostic role of coagulation products as biomarkers of liver decompensation (ascites, variceal hemorrhage, and hepatic encephalopathy) and liver-related mortality. Finally, we evaluate the current evidence on the application of antiplatelet and anticoagulant therapies for prophylaxis of hepatic decompensation or prevention of the progression of liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.